These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 31046913)

  • 21. Adherence to multiple sclerosis disease-modifying therapies in Ontario is low.
    Wong J; Gomes T; Mamdani M; Manno M; O'Connor PW
    Can J Neurol Sci; 2011 May; 38(3):429-33. PubMed ID: 21515501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abdominal wall ulceration and mucinosis secondary to recombinant human interferon-beta-1b.
    Wells J; Kossard S; McGrath M
    Australas J Dermatol; 2005 Aug; 46(3):202-4. PubMed ID: 16008658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fixed drug eruption with interferon-beta-1b.
    Tai YJ; Tam M
    Australas J Dermatol; 2005 Aug; 46(3):154-7. PubMed ID: 16008645
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis.
    Reynolds MW; Stephen R; Seaman C; Rajagopalan K
    Curr Med Res Opin; 2010 Mar; 26(3):663-74. PubMed ID: 20070144
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders.
    Durelli L; Barbero P; Bergui M; Versino E; Bassano MA; Verdun E; Ferrero B; Rivoiro C; Ferrero C; Picco E; Ripellino P; Viglietti D; Giuliani G; Montanari E; Clerico M;
    J Neurol; 2008 Sep; 255(9):1315-23. PubMed ID: 18825438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis.
    Webster GF; Knobler RL; Lublin FD; Kramer EM; Hochman LR
    J Am Acad Dermatol; 1996 Feb; 34(2 Pt 2):365-7. PubMed ID: 8655728
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aseptic steatonecrosis in a patient with multiple sclerosis under treatment with interferon-beta 1b.
    Ramos L; Busca C; Robles A
    Med Clin (Barc); 2018 Feb; 150(3):122. PubMed ID: 28864085
    [No Abstract]   [Full Text] [Related]  

  • 28. Lobular panniculitis at the site of subcutaneous interferon beta injections for the treatment of multiple sclerosis can histologically mimic pancreatic panniculitis. A study of 12 cases.
    Ball NJ; Cowan BJ; Hashimoto SA
    J Cutan Pathol; 2009 Mar; 36(3):331-7. PubMed ID: 19032383
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Severe liver dysfunction possibly caused by the combination of interferon beta-1b therapy and melilot (sweet clover) supplement.
    Tamura S; Warabi Y; Matsubara S
    J Clin Pharm Ther; 2012 Dec; 37(6):724-5. PubMed ID: 22642738
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimization of the safety and efficacy of interferon beta 1b and azathioprine combination therapy in multiple sclerosis.
    Pulicken M; Bash CN; Costello K; Said A; Cuffari C; Wilterdink JL; Rogg JM; Mills P; Calabresi PA
    Mult Scler; 2005 Apr; 11(2):169-74. PubMed ID: 15794390
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and tolerability of a 'refrigeration-free' formulation of interferon beta-1b--results of a double-blind, multicentre, comparative study in patients with relapsing-remitting or secondary progressive multiple sclerosis.
    Baum K;
    J Int Med Res; 2006; 34(1):1-12. PubMed ID: 16604818
    [TBL] [Abstract][Full Text] [Related]  

  • 32. No evidence for increased frequency of autoantibodies during interferon-beta1b treatment of multiple sclerosis.
    Kivisäkk P; Lundahl J; von Heigl Z; Fredrikson S
    Acta Neurol Scand; 1998 May; 97(5):320-3. PubMed ID: 9613562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early treatment and dose optimisation BENEFIT and BEYOND.
    Hartung HP
    J Neurol; 2005 Sep; 252 Suppl 3():iii44-iii50. PubMed ID: 16170501
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Local pain during REBIF injection is not due to acidic pH.
    Buttmann M; Goebeler M; Rieckmann P
    J Neurol Neurosurg Psychiatry; 2004 Jul; 75(7):1078. PubMed ID: 15201384
    [No Abstract]   [Full Text] [Related]  

  • 35. The importance of maintaining effective therapy in multiple sclerosis.
    Durelli L; Clerico M
    J Neurol; 2005 Sep; 252 Suppl 3():iii38-iii43. PubMed ID: 16170500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab.
    Barbero P; Bergui M; Versino E; Ricci A; Zhong JJ; Ferrero B; Clerico M; Pipieri A; Verdun E; Giordano L; Durelli L;
    Mult Scler; 2006 Feb; 12(1):72-6. PubMed ID: 16459722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Local reactions associated with subcutaneous injections of both beta-interferon 1a and 1b.
    García-F-Villalta M; Daudén E; Sánchez J; Fraga J; Ramo C; García-Díez A
    Acta Derm Venereol; 2001 May; 81(2):152. PubMed ID: 11501663
    [No Abstract]   [Full Text] [Related]  

  • 38. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients.
    Gneiss C; Tripp P; Reichartseder F; Egg R; Ehling R; Lutterotti A; Khalil M; Kuenz B; Mayringer I; Reindl M; Berger T; Deisenhammer F
    Mult Scler; 2006 Dec; 12(6):731-7. PubMed ID: 17263000
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interferon beta-1b-induced postmenopausal bleeding in a patient with multiple sclerosis.
    Perlman B; Heller D; Cracchiolo B
    Climacteric; 2016 Dec; 19(6):599-600. PubMed ID: 27749097
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Activation of psoriasis in patients undergoing treatment with interferon-beta].
    Navne JE; Hedegaard U; Bygum A
    Ugeskr Laeger; 2005 Aug; 167(32):2903-4. PubMed ID: 16109199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.